



Federal Employee Program
Blue Cross Blue Shield Association
750 9th St NW, Suite 900
Washington, D.C. 20001
1-800-624-5060
Fax 1-877-378-4727

5.20.003

| | | | |
|--------------------|--------------------|------------------------------|-----------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2026 |
| Subsection: | Biologicals | Original Policy Date: | March 8, 2002 |
| Subject: | IVIG | Page: | 1 of 16 |

Last Review Date: December 12, 2025

IVIG (intravenous immunoglobulin)

Description

IVIG Immune Globulin – Asceniv**, Alyglo, Bivigam, Flebogamma, Gammagard, Gammagard S/D, Gammaked, Gammaplex, Gamunex-C, Octagam, Panzyga, Privigen, Qivigy*

*This medication is included in this policy but is not available on the market as of yet

**Product covered on the medical benefit only

Background

Immune globulin products from human plasma were first used in the 1950s and 60s to treat immune deficiency. These initial preparations were given either intramuscularly or subcutaneously to avoid the severe shock-like reactions from intravenous administration. In the early 1980s chemical and enzymatic modifications of the pooled plasma provided a preparation suitable for intravenous administration. Intravenous immunoglobulin (IVIG) products are prepared from pooled donations exceeding 10,000 liters (1).

IVIG is used to treat various autoimmune, infectious, and idiopathic diseases (1).

Regulatory Status

FDA-approved indications: The immune globulins addressed by this policy are FDA-approved for use in one or more of the following conditions: (2-14)

- Primary immune deficiency (PID)
- Acute and Chronic Thrombocytopenic Purpura (ITP)

| | | | |
|--------------------|--------------------|------------------------------|-----------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2026 |
| Subsection: | Biologicals | Original Policy Date: | March 8, 2002 |
| Subject: | IVIG | Page: | 2 of 16 |

- Prevention of bacterial and viral infections in patients with hypogammaglobulinemia and/or recurrent bacterial and viral infections associated with B-cell Chronic Lymphocytic Leukemia (CLL)
- Prevention of coronary artery aneurysms associated with Kawasaki syndrome
- Multifocal Motor Neuropathy (MMN)
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Off-Label Uses: (15-32)

1. Prophylaxis of bacterial and viral infections in pediatric human immunodeficiency virus (HIV) infection
2. Prophylaxis of bacterial and viral infections in bone marrow transplant (BMT)/hematopoietic stem cell transplant (HSCT) recipients
3. Dermatomyositis
4. Polymyositis
5. Myasthenia gravis
6. Guillain-Barre syndrome
7. Lambert-Eaton myasthenic syndrome
8. Fetal/neonatal alloimmune thrombocytopenia
9. Parvovirus B19-induced pure red cell aplasia
10. Stiff-person syndrome
11. End-stage renal disease (ESRD) to improve the chances of successful kidney transplantation
12. Peripheral blood progenitor cell (PBPC) collection
13. Umbilical Cord Stem Cell Transplantation
14. Inclusion-body myositis
15. Multiple sclerosis
16. Secondary immunosuppression associated with hematological malignancy
17. Autoimmune encephalitis

Use of immune globulin to treat immunosuppression secondary to hematological malignancy is supported by data from several clinical trials. This acquired hypogammaglobulinemia is thought to occur, in part, due to the use of therapies targeting B-cells, and due to the clonal proliferation of abnormal B-cells as part of the hematological malignancy's disease process. The decision to supplement with exogenous IVIG should be made after review of patient's physical history and IgG serum concentrations indicating hypogammaglobulinemia (serum IgG < 500 mg/dL or ≥ 2 standard deviations below the mean concentration for age) (1, 31).

| | | | |
|--------------------|--------------------|------------------------------|-----------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2026 |
| Subsection: | Biologicals | Original Policy Date: | March 8, 2002 |
| Subject: | IVIG | Page: | 3 of 16 |

There are various types of immune-mediated encephalopathy, including anti-NMDA encephalitis, VGKG-associated limbic encephalopathies, and Hu and Ma2-mediated encephalitis. These have been seen in patients both with cancer and cancer-free of all ages, notably in young adults and children. First-line treatment, showing moderate success, includes the use of IVIGs (16-17).

Immune globulin use is associated with increased risk of thrombosis, particularly in the elderly and patients with risk factors such as cardiovascular disease, hypercoagulopathy, those on estrogen therapy, and patients with central venous catheters. Patients should be monitored carefully for signs and symptoms of thrombosis both at the time of infusion and after infusion. For those patients who will be self-administering the medication, practitioners need to instruct the patients and caregivers on how to monitor for signs and symptoms of thrombosis. Thrombosis may occur regardless of the route of administration (2-14).

IVIG products have been associated with renal dysfunction, acute renal failure, osmotic nephrosis, and death. Patients predisposed to acute renal failure include patients with any degree of pre-existing renal insufficiency, diabetes mellitus, > 65 years of age, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs (2-14).

Other potential complications to monitor include the following (2-14):

Immunoglobulin A deficiency: People with this condition have the potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA.

Aseptic meningitis syndrome (AMS): Rare occurrences of AMS have been reported in association with IVIG treatment. AMS usually begins within several hours to 2 days following IVIG treatment and is characterized by symptoms including severe headache, drowsiness, fever, photophobia, painful eye movements, muscle rigidity, nausea, and vomiting. AMS may occur more frequently in association with high-dose (2 g/kg) IVIG treatment. Discontinuation of IVIG treatment has resulted in remission of AMS within several days without sequelae.

Bleeding complications: Bleeding complications may be encountered in patients with thrombocytopenia or other bleeding disorders.

Severe reactions: Severe reactions, such as anaphylaxis or angioneurotic edema, have been reported in association with IV immunoglobulins, even in patients not known to be sensitive to human immunoglobulins or blood products.

| | | | |
|--------------------|--------------------|------------------------------|-----------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2026 |
| Subsection: | Biologicals | Original Policy Date: | March 8, 2002 |
| Subject: | IVIG | Page: | 4 of 16 |

Related policies

Atgam, Cabilivi, GamaSTAN, SCIG

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

IVIG may be considered **medically necessary** if the conditions indicated below are met.

IVIG may be considered **investigational** for all other indications.

Prior-Approval Requirements

Diagnoses

Patient must have **ONE** of the following documented indications:

1. Primary immunodeficiency disease (PID) with **ONE** of the following:
 - a. Hypogammaglobulinemia, IgG subclass deficiency, selective IgA deficiency, selective IgM deficiency, or specific antibody deficiency with **ALL** of the following:
 - i. Documented history of recurrent bacterial and viral infections
 - ii. Impaired antibody response to pneumococcal vaccine
 - iii. **ONE** of the following pre-treatment laboratory findings:
 - 1) Hypogammaglobulinemia: IgG < 500 mg/dL or \geq 2 SD below the mean for age
 - 2) Selective IgA deficiency: IgA level < 7 mg/dL with normal IgG and IgM levels
 - 3) Selective IgM deficiency: IgM level < 30 mg/dL with normal IgG and IgA levels
 - 4) IgG subclass deficiency: IgG1, IgG2, or IgG3 \geq 2 SD below the mean for the age assessed on at least 2 occasions; normal IgG (total) and IgM levels, normal/ low IgA levels
 - 5) Specific antibody deficiency: normal IgG, IgA and IgM levels

| | | | |
|--------------------|--------------------|------------------------------|-----------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2026 |
| Subsection: | Biologicals | Original Policy Date: | March 8, 2002 |
| Subject: | IVIG | Page: | 5 of 16 |

- b. SCID (severe combined immunodeficiency disease) or Agammaglobulinemia with **ONE** of the following:
 - i. Confirmed diagnosis by genetic or molecular testing
 - ii. Pretreatment IgG level < 200mg/dL
 - iii. Absence or very low number of T cells (CD3 T cells < 300/microliter) or presence of maternal T cells in the circulation (SCID only)
- c. Wiskott-Aldrich syndrome, DiGeorge syndrome, or ataxia-telangiectasia (or other non SCID combined immunodeficiency) with **ALL** of the following:
 - i. Confirmed diagnosis by genetic or molecular testing
 - ii. Documented history of recurrent bacterial and viral infections
 - iii. Impaired antibody response to pneumococcal vaccine
- d. CVID (common variable immunodeficiency disease) with **ALL** of the following:
 - i. Age 4 years and older
 - ii. Documented history of recurrent bacterial and viral infections
 - iii. Impaired antibody response to pneumococcal vaccine
 - iv. Other causes of immune deficiency have been excluded (e.g., drug induced, genetic disorders, infectious diseases such as HIV, malignancy, etc.)
 - v. Pretreatment IgG level < 500mg/dL or \geq 2 SD below the mean for the age

2. Idiopathic thrombocytopenic purpura (ITP)

- a. Newly diagnosed ITP (diagnosed with in the past 3 months) must have **ONE** of the following:
 - i. Children (<18 years of age) with **ONE** of the following:
 - 1) Significant bleeding symptoms (mucosal bleeding or moderate /severe bleeding)
 - 2) High risk for bleeding
 - 3) Rapid increase in platelets is required (e.g., surgery or procedure)
 - ii. Adults (\geq 18 years of age) with **ONE** of the following:
 - 1) Platelet count < 30,000/mcL
 - 2) Platelet count < 50,000/mcL and significant bleeding symptoms, high risk for bleeding or rapid increase in platelets is required

| | | | |
|--------------------|--------------------|------------------------------|-----------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2026 |
| Subsection: | Biologicals | Original Policy Date: | March 8, 2002 |
| Subject: | IVIG | Page: | 6 of 16 |

AND the following:

- 1) Corticosteroid therapy is contraindicated and IVIG will be used alone or IVIG will be used in combination with corticosteroid therapy
- b. Chronic/persistent ITP (> 3 months from diagnosis)

AND ONE of the following:

- i. Platelet count < 30,000/mcL
- ii. Platelet count < 50,000/mcL and significant bleeding symptoms, high risk for bleeding or rapid increase in platelets is required

AND the following:

- i. Relapse after previous response to IVIG or inadequate treatment response, intolerance, or contraindication to corticosteroid therapy

- c. ITP unresponsive to first-line therapy

AND ONE of the following:

- i. Platelet count < 30,000/mcL
- ii. Platelet count < 50,000/mcL and significant bleeding symptoms, high risk for bleeding or rapid increase in platelets is required

AND the following:

- ii. Relapse after previous response to IVIG or inadequate treatment response, intolerance, or contraindication to corticosteroid therapy

- d. Adults with refractory ITP after splenectomy must have **ONE** of the following:

- i. Platelet count < 30,000/mcL
- ii. Significant bleeding symptoms

- e. ITP in pregnant women

3. B-cell chronic lymphocytic leukemia with **ALL** of the following:

- a. IVIG is prescribed for prophylaxis of bacterial and viral infections
- b. Documented history of recurrent sinopulmonary infections requiring intravenous antibiotics or hospitalization
- c. Pretreatment serum IgG level < 500 mg/dL

| | | | |
|--------------------|--------------------|------------------------------|-----------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2026 |
| Subsection: | Biologicals | Original Policy Date: | March 8, 2002 |
| Subject: | IVIG | Page: | 7 of 16 |

4. Kawasaki syndrome
5. Prophylaxis of bacterial and viral infections in Bone Marrow Transplantation (BMT) / Hematopoietic Stem Cell Transplantation (HSCT) recipients with **ALL** of the following:
 - a. IVIG is prescribed for prophylaxis of bacterial and viral infections
 - b. **ONE** of the following:
 - i. IVIG is requested within the first 100 days post-transplant
 - ii. Pretreatment serum IgG level < 400 mg/dL
6. Peripheral blood progenitor cell (PBPC) collection
7. Umbilical Cord Stem Cell Transplantation
8. Prophylaxis of bacterial and viral infections in HIV-Infected pediatric patients with **ALL** of the following:
 - a. Patient is ≤ 12 years of age
 - b. Patient is using as **ONE** of the following:
 - i. Primary prophylaxis:
 - 1) Pretreatment serum IgG level < 400 mg/dL
 - ii. Secondary prophylaxis:
 - 1) Documented recurrent bacterial and viral infections (> 2 serious infections in a year)
 - 2) **NOT** able to take combination antiretroviral therapy
 - 3) Antibiotic prophylaxis **NOT** effective
9. Polymyositis or Dermatomyositis with **ALL** of the following:
 - a. Documented clinical features of diagnosis (e.g., elevated muscle enzymes, muscle biopsy, supportive diagnostic tests)
 - b. Inadequate response, intolerance, or contraindication to first-line treatments (corticosteroids or immunosuppressants)
10. Inclusion-body myositis
11. Guillain-Barre syndrome (GBS) with **ALL** of the following:
 - a. Physical mobility is severely affected such that patient requires an aid to walk
 - b. IVIG therapy will be initiated within 2 weeks of symptom onset

| | | | |
|--------------------|--------------------|------------------------------|-----------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2026 |
| Subsection: | Biologicals | Original Policy Date: | March 8, 2002 |
| Subject: | IVIG | Page: | 8 of 16 |

12. Fetal alloimmune thrombocytopenia (F/NAIT)
13. Myasthenia gravis with **ONE** of the following:
 - a. Worsening weakness includes an increase in any of the following symptoms:
 - i. Diplopia
 - ii. Ptosis
 - iii. Blurred vision
 - iv. Dysarthria
 - v. Dysphagia
 - vi. Difficulty chewing
 - vii. Impaired respiratory status
 - viii. Fatigue
 - ix. Limb weakness
 - b. Pre-operative management
14. Multiple sclerosis
15. Multifocal motor neuropathy (MMN) with **ALL** of the following:
 - a. Weakness without objective sensory loss in 2 or more nerves
 - b. Electrodiagnostic studies are consistent with motor conduction block
 - c. Normal sensory nerve conduction studies
16. Secondary immunosuppression associated with hematological malignancy with **ALL** of the following:
 - a. Hypogammaglobulinemia: IgG < 500 mg/dL or ≥ 2 SD below the mean for age
 - b. Documented history of recurrent bacterial and viral infections
 - c. Impaired antibody response to pneumococcal vaccine
17. Chronic inflammatory demyelinating polyneuropathy (CIDP) with **ALL** of the following:
 - a. Moderate to severe functional disability
 - b. Electrodiagnostic studies are consistent with multifocal demyelinating abnormalities
18. Autoimmune encephalitis
 - a. Confirmation of diagnosis with **TWO** of the following tests:
 - i. Neuroimaging

| | | | |
|--------------------|--------------------|------------------------------|-----------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2026 |
| Subsection: | Biologicals | Original Policy Date: | March 8, 2002 |
| Subject: | IVIG | Page: | 9 of 16 |

- ii. Electroencephalography (EEG)
- iii. Lumbar puncture
- iv. Serologic testing

19. Lambert-Eaton myasthenic syndrome (LEMS)
20. Parvovirus B 19-induced pure red cell aplasia (PRCA)
21. Stiff-person syndrome with **ALL** of the following:
 - a. Inadequate treatment response, intolerance, or contraindication to first-line treatments (benzodiazepine or baclofen)
22. End-stage renal disease (ESRD)
 - a. Used to improve the chances of successful kidney transplantation

AND ONE of the following for **ALL** indications:

- a. Monitor patients carefully for signs and symptoms of thrombosis both at the time of infusion and after infusion
- b. Patients or caregivers have been instructed on how to monitor for signs and symptoms of thrombosis when self-administering the medication

AND the following for **ALL** indications:

- a. **NO** concurrent therapy with another IVIG / SCIG product

Prior – Approval Renewal Requirements

Diagnoses

Patient must have **ONE** of the following:

1. Primary immunodeficiency disease (PID) with **ONE** of the following:
 - a. Hypogammaglobulinemia, IgG subclass deficiency, selective IgA deficiency, selective IgM deficiency, or specific antibody deficiency
 - b. SCID (severe combined immunodeficiency disease) or Agammaglobulinemia
 - c. Wiskott-Aldrich syndrome, DiGeorge syndrome, or ataxia-telangiectasia (or other non SCID combined immunodeficiency)
 - d. CVID (common variable Immunodeficiency disease)
 - i. Age 4 years and older

| | | | |
|--------------------|--------------------|------------------------------|-----------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2026 |
| Subsection: | Biologicals | Original Policy Date: | March 8, 2002 |
| Subject: | IVIG | Page: | 10 of 16 |

AND ALL of the following:

- a. Documented reduction in frequency of bacterial and viral infections since initiation
- b. IgG trough levels are monitored at least yearly and maintained at or above the lower range of normal for age (when applicable for indication)
- c. The prescriber will re-evaluate the dose of the IVIG and reconsider a dose adjustment

2. Idiopathic thrombocytopenic purpura (ITP)
3. B-cell chronic lymphocytic leukemia
 - a. Reduction in frequency of bacterial and viral infections has been documented since initiation
4. Kawasaki syndrome
5. Prophylaxis of bacterial and viral infections in Bone Marrow Transplantation (BMT) / Hematopoietic Stem Cell Transplantation (HSCT) recipients
 - a. Reduction in frequency of bacterial and viral infections has been documented since initiation
6. Peripheral blood progenitor cell (PBPC) collection
7. Umbilical Cord Stem Cell Transplantation
8. Prophylaxis of bacterial and viral infections in HIV-Infected pediatric patients
 - a. Patient is \leq 12 years of age
 - b. Reduction in frequency of bacterial and viral infections has been documented since initiation
9. Polymyositis or dermatomyositis
 - a. Significant improvement in disability and maintenance of improvement since initiation
10. Inclusion-body myositis
11. Guillain-Barre Syndrome (GBS)

| | | | |
|--------------------|--------------------|------------------------------|-----------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2026 |
| Subsection: | Biologicals | Original Policy Date: | March 8, 2002 |
| Subject: | IVIG | Page: | 11 of 16 |

12. Fetal alloimmune thrombocytopenia (F/NAIT)
13. Myasthenia gravis
14. Multiple sclerosis
15. Multifocal motor neuropathy (MMN)
 - a. Significant improvement in disability and maintenance of improvement since initiation
16. Secondary immunosuppression associated with hematological malignancy
 - a. Documented reduction in frequency of bacterial and viral infections since initiation
17. Chronic inflammatory demyelinating polyneuropathy (CIDP) with **ALL** of the following:
 - a. Significant improvement in disability and maintenance of improvement since initiation
 - b. IVIG is being used at the lowest effective dose and frequency
 - c. Chronic stable patients have been tapered and/or treatment withdrawn to determine whether continued treatment is necessary
18. Autoimmune encephalitis
 - a. Improvement in disability and maintenance of improvement since initiation confirmed by neurological exam
19. Lambert-Eaton syndrome (LEMS)
20. Parvovirus B 19-induced pure red cell aplasia (PRCA)
21. Stiff-person syndrome
22. End-stage renal disease (ESRD)
 - a. Used to improve the chances of successful kidney transplantation

AND ONE of the following for **ALL** indications:

| | | | |
|--------------------|--------------------|------------------------------|-----------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2026 |
| Subsection: | Biologics | Original Policy Date: | March 8, 2002 |
| Subject: | IVIG | Page: | 12 of 16 |

- a. Monitor patients carefully for signs and symptoms of thrombosis both at the time of infusion and after infusion
- b. Patients or caregivers have been instructed on how to monitor for signs and symptoms of thrombosis when self-administering the medication

AND the following for **ALL** indications:

- b. **NO** concurrent therapy with another IVIG / SCIG product

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Duration 12 months

Prior – Approval Renewal Limits

Same as above

Rationale

Summary

Immune globulin products are primarily used to treat immune deficiency. They are also used off-label to treat other conditions such as myasthenia gravis and multiple sclerosis. The IVIG products differ in the preparation method, viral inactivation steps, stabilizing agent, osmolality, and IgA content (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of IVIG while maintaining optimal therapeutic outcomes.

References

1. Ueda M, Berger M, Gale RP, and Lazarus HM. Blood Reviews. 2018; 32(2): 106-115.
2. Asceniv [package insert]. Boca Raton, FL: ADMA Biologics; April 2019.
3. Flebogamma [package insert]. Barcelona, Spain: Grifols, S.A.; September 2019.
4. Gammagard [package insert]. Lexington, MA: Baxalta US Inc.; March 2021.

| | | | |
|--------------------|--------------------|------------------------------|-----------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2026 |
| Subsection: | Biologics | Original Policy Date: | March 8, 2002 |
| Subject: | IVIG | Page: | 13 of 16 |

5. Gammagard S/D [package insert]. Lexington, MA: Baxter US Inc.; March 2021.
6. Gammaked [package insert]. Research Triangle Park, NC: Grifols Therapeutics LLC; January 2020.
7. Gammaplex [package insert]. Durham, NC: Bio Products Laboratory; September 2019.
8. Gamunex-C [package insert]. Research Triangle Park, NC: Grifols Therapeutics LLC; January 2020.
9. Octagam [package insert]. Paramus, NJ: Octapharma USA Inc.; February 2020.
10. Privigen [package insert]. Kankakee, IL: CSL Behring LLC; March 2019.
11. Bivigam [package insert]. Boca Raton, FL: Biotest Pharmaceuticals Corporation. May 2021.
12. Panzyga [package insert]. Paramus, NJ: Octapharma USA, Inc.; February 2021.
13. Alyglo [package insert]. Yongin-si, Republic of Korea: GC Biopharma Corp.; December 2023.
14. Qivigy [package insert]. Fort Lee, NJ: Kedrion Biopharma Inc.; September 2025.
15. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. *Lancet Neurol.* 2011;10(1):63.
16. Nosadini M, Mohammad SS, Ramanathan S, et al. Immune therapy in autoimmune encephalitis: a systematic review. *Expert Rev Neurother.* 2015;15(12):1391-419.
17. Siberry, G, Abzug, MJ, Nachman, S, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HI V-Infected Children. *Pediatr Infect Dis J.* 2013; 32 Suppl 2(0 2): i – KK4.
18. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. *Biol Blood Marrow Transplant.* 2009;1 5(1 0):1 143-1238.
19. Donofrio PD, Berger A, Brannagan TH 3rd, et al. Consensus statement: the use of intravenous immunoglobulin in the treatment of neuromuscular conditions report of the AANEM ad hoc committee. *Muscle Nerve.* 2009;40(5):890-900.
20. Elovaara I, Apostolski S, van Doorn P et al. EFNS guidelines for the use of intravenous immunoglobulin treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. *Eur J Neurol.* 2008;15(9):893-908.
21. Patwa HS, Chaudhry V, Katzberg H, et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology.* 2012;78(1 3);1 009-1015.
22. Picard C, Al-Herz W, Bousfiha A, et al. Primary immunodeficiency diseases: an update on the classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency. *J Clin Immunol.* 2015; 35(8):696-726.
23. Orange JS, Ballow M, Stiehm ER, et al. Use and interpretation of diagnostic vaccination in

| | | | |
|--------------------|--------------------|------------------------------|-----------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2026 |
| Subsection: | Biologicals | Original Policy Date: | March 8, 2002 |
| Subject: | IVIG | Page: | 14 of 16 |

primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest section of the American Academy of Allergy, Asthma and Immunology. *J Allergy Clin Immunol.* 2012;130:S1-524.

24. Ameratunga R, Woon ST, Gillis D, Koopmans W, Steele R. New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin. *Clinical Exp Immunol.* 2013;174(2):203-11.
25. Immune Deficiency Foundation. About primary immunodeficiencies. Specific disease types. <http://primaryimmune.org/about-primary-immunodeficiencies/specific-disease-types/>. Accessed September 9, 2021.
26. Immune Deficiency Foundation. Diagnostic and Clinical Care Guidelines for Primary Immunodeficiency Diseases. 3rd edition. Towson, MD: Immune Deficiency Foundation; 2015. https://primaryimmune.org/sites/default/files/publications/2015-Diagnostic-and-Clinical-Care-Guidelines-for-PI_1.pdf.
27. Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society- first revision. *Eur J Neurol.* 2010;17(3):356-363.
28. Olney RK, Lewis RA, Putnam TO, Campellone JV. Consensus criteria for the diagnosis of multifocal motor neuropathy. *Muscle Nerve.* 2003;27:117-121.
29. Dalakas M. Inflammatory muscle diseases. *N Eng/ J Med.* 2015;372(18):1734-1747.
30. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. *Blood.* 2011;117(16):4190-4207.
31. Anderson D, Ali K, Blanchette V, et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. *Transfus Med Rev.* 2007;21(2 suppl 1):S9-S56.
32. Jordan SC, Tyan D, Stablein D, et al. Evaluation of Intravenous Immunoglobulin as an Agent to Lower Allosensitization and Improve Transplantation in Highly Sensitized Adult Patients with End-Stage Renal Disease: Report of the NIH IG02 Trial. *J Am Soc Nephrol* (2004) 15:3256-62. 10.1097/01.ASN.0000145878.92906.9F

Policy History

| Date | Action |
|----------------|---|
| September 2008 | FDA approved Gamunex for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) on 9/12/08. CIDP is approvable as off-label use for all Immune Globulins |
| March 2009 | Added PrIVIGen to Immune Globulins and updated format. |
| November 2009 | Off-label uses clarified; removed Gammimune, Gammar PIV, Venoglobulin-1 and Venoglobulin-S; all of which are no longer on the market. |

| | | | |
|--------------------|--------------------|------------------------------|-----------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2026 |
| Subsection: | Biologicals | Original Policy Date: | March 8, 2002 |
| Subject: | IVIG | Page: | 15 of 16 |

| | |
|----------------|--|
| April 2010 | Line extension of Hizentra, FDA approved 3/4/2010, for the treatment of primary immunodeficiency (PI). Removed Polygam, IVEEGAM and Panglobulin which are no longer on the market. Added ICD-10 codes. |
| May 2010 | Line extension of Gammaplex, FDA approved 12/11/2009, for primary humoral immunodeficiency. |
| September 2011 | Line extension of Gamunex-C, FDA approved 10/14/2011, for primary immunodeficiency. |
| September 2011 | Line extension of Gammaked, FDA approved 8/3/2011, for the treatment of primary humoral immunodeficiency disease (PI), idiopathic thrombocytopenic purpura (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP). |
| December 2012 | Annual editorial review and update |
| February 2013 | Line addition of BIVIGAM |
| June 2013 | Annual editorial review and reference update |
| June 2013 | FDA: New Boxed Warning for Clot Risk with Immune Globulin, reference update |
| December 2013 | Annual editorial review and reference update |
| February 2014 | Revision to criteria requirements that self-administering patients are instructed to how to monitor for signs and symptoms of thrombosis. |
| September 2014 | Line-addition of Octagam 10%. Reference update. |
| November 2014 | Addition of HyQvia for all indications |
| December 2014 | Addition of a line-extension of Gamunex-C 40/400ml |
| March 2015 | Annual editorial review and reference update |
| June 2016 | Annual editorial review and reference update |
| | Addition of CVID (common variable Immunodeficiency disease) |
| August 2016 | Policy code changed from 5.05.03 to 5.20.03 |
| October 2016 | Addition of Autoimmune encephalitis |
| | Transfer of Hizentra and Hyqvia from criteria to 5.20.08 |
| | Addition of all indication pre-requisites and new indications: Lambert-Eaton Myasthenic syndrome (LEMS), Parvovirus B 19-induced pure red cell aplasia (PRCA), Stiff-person Syndrome, Guillain-Barre Syndrome (GBS) |
| December 2016 | Annual review |
| March 2017 | Annual review |
| October 2017 | Addition of initiation requirement for Autoimmune encephalitis with confirmation of diagnosis with TWO of the following tests: neuroimaging, electroencephalography (EEG), lumbar puncture, or serologic testing and renewal requirement of improvement in disability and maintenance of improvement since initiation confirmed by neurological exam |
| | Addition of NO concurrent therapy with another IVIG / SCIG product |
| December 2017 | Annual review |
| January 2018 | Change of Myasthenia gravis requirements from ALL to ONE of the following |

| | | | |
|--------------------|--------------------|------------------------------|-----------------|
| Section: | Prescription Drugs | Effective Date: | January 1, 2026 |
| Subsection: | Biologicals | Original Policy Date: | March 8, 2002 |
| Subject: | IVIG | Page: | 16 of 16 |

| | |
|----------------|--|
| March 2018 | Annual review |
| October 2018 | Addition of Panzyga |
| November 2018 | Annual review and reference update. Carimune NF removed from market |
| June 2019 | Annual review |
| September 2019 | Annual review |
| December 2019 | Addition of Asceniv |
| March 2020 | Annual review |
| June 2021 | Annual review and reference update |
| September 2021 | Per FEP: changed "Neoplastic disease" indication to "Secondary immunosuppression associated with hematological malignancy" and added initiation requirement "Hypogammaglobulinemia: IgG < 500 mg/dL or \geq 2 SD below the mean for age" |
| December 2021 | Annual review |
| June 2022 | Annual review |
| October 2022 | Per FEP, added requirements for Secondary Immunosuppression associated with Hematological Malignancy: documented history of recurrent bacterial and viral infections and impaired antibody response to pneumococcal vaccine for initiation; documented reduction in frequency of bacterial and viral infections since initiation for continuation. Changed policy number to 5.20.003 |
| December 2022 | Annual review |
| January 2023 | Per FEP, addition of off-label use to improve chances of successful kidney transplantation in end-stage renal disease (ESRD) |
| March 2023 | Annual editorial review |
| March 2024 | Annual review |
| August 2024 | Addition of Alyglo to PA |
| September 2024 | Annual review |
| March 2025 | Annual editorial review |
| December 2025 | Annual editorial review. Addition of Qivigy to PA. Asceniv moved to coverage on medical benefit only |

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on December 12, 2025 and is effective on January 1, 2026.